Leinco Technologies

RANKL Blocking Peptide

Product Code:
 
LEI-R1243
Product Group:
 
Peptides
Regulatory Status:
 
RUO
Shipping:
 
Ambient
Storage:
 
Store this peptide in working aliquots at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-R1243-50ug50 ug£216.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Related Products
  • Show All

Further Information

Concentration:
0.2 mg/ml
Format:
This peptide is formulated in PBS pH 7.2 (0.01 M Sodium Phosphate, 0.13 M NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide.
Formulation:
This peptide is formulated in PBS pH 7.2 (0.01 M Sodium Phosphate, 0.13 M NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide.
Long Description:
RANKL (Receptor Activator for Nuclear Factor κ B Ligand), also known as TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and ODF (osteoclast differentiation factor), is a member of the tumor necrosis factor family cytokine.1 RANKL is essential for osteoclast formation, activation, and survival.2 RANKL through interaction with its receptor RANK can modulate matrix degradation and inflammation.3 RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy. Consequently, novel drugs specifically targeting RANK, RANKL, and their signaling pathways in osteoclasts are expected to revolutionize the treatment of various ailments associated with bone loss, such as arthritis, periodontal disease, cancer metastases, and osteoporosis.4
Target:
sRANKL

References

1. H Takayanagi et al. (2003) Arthritis Res Ther. 5: 20 2. Kostenuik PJ et al. (2005) Endocrinology 146: 3235 3. Holven KB et al. (2009) Stroke 40: 241 4. Penninger JM et al. (2008) Ann N Y Acad Sci. 1143: 123